SPOTLIGHT -
April 11th 2024
Is it possible to win in Asia’s private market?
February 8th 2024
The three key themes likely to shape pharma fortunes in 2024.
January 19th 2024
A growing number of domestic drug developers are setting their sights on overseas markets.
November 16th 2023
An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.
November 3rd 2023
Raja discusses how the pharma industry can improve its ecological impact.
China Expedites Price Reduction of Anticancer Drugs
In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.
Biotech Investment: Reigning in Spain
Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.
European Drug Innovators Face Tough Fight to Maintain Research Incentives
Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.
Country Report: Portugal
Behind an economic revival in Portugal, including healthcare spending growth, the nation’s life sciences sector is benefiting as well, with Portugal diverging from the European averages to show an increase in R&D and innovation.
Emerging Collaboration in EU Drug Pricing and Reimbursement: Table 1
Emerging Collaboration in EU Drug Pricing and Reimbursement Table 2
Pharma AI Requires a New Approach to Governance
Artificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.
The Diabetes Market in China
With China predicted to account for 48% of the global diabetes population by 2045, Jin Zhang looks at how the country's domestic pharma companies are faring in this treatment area.
Japan: Balancing Cost and Innovation through Pricing
Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.
EMA Relocation Countdown: Some Industry Viewpoints
Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.
Pathways to Potential in Europe's Pharmerging Markets
Filip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.
China’s Biopharma Rise: Opportunities and Threats
Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
New Jersey is still a top pick for companies when it comes to pharma.
Country Report: India
The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.
Foreign Biotech Eyes New Jersey as Top Pharma Location
Korean biotech opens first U.S. headquarters in New Jersey to better control clinical trials as it looks for strategic partnerships in the U.S.
Korean Biotech Talks About U.S. Company Launch
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Nurse Educators: Bridging China's Patient Care Gap
China's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.
Deciphering the EU Health Policy Hieroglyphs
Figuring out the workings of the EU in topics related to health can be akin to deciphering Egyptian hieroglyphs, making it challenging for companies to plan ahead, writes Reflector.
China's Removal of Imported Drug Tariffs
On May 1, China eliminated the tariff on 28 categories of imported drugs. Jin Zhang looks at the implications for foreign and domestic pharma companies.
Can Trump Plan Serve as Model for What Ails Europe?
Weighing the crossover effect of US’s new pricing blueprint.
The PD-1/PD-L1 Race in China
The PD-1/PD-L1 market in China is heating up and companies there have made a series of advances, writes Jin Zhang.
Pharm Exec's Top 50 Companies 2018
Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.
Gauging the Collaborative Spirit in European Health
Pair of EU meetings, while well-meant, offered little action and beg the question-what’s the true merit in working together?
Big Data & Japan's Aging Population: Opening the Door for US Pharma
Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.
China's In Vitro Diagnostics Market 2018
Jin Zhang identifies the major domestic companies in China’s IVD industry.
Biosimilars in China
Jin Zhang discusses the research and development of several major biologics in China.
China’s CAR-T Therapy Race
Jin Zhang looks at how China's CART-T therapy race is heating up.
A Plus ça Change Feeling on European Pharma
Looking back at the agenda of a 1985 EFPIA conference demonstrates that, three decades on, the European drug industry is still seeking a pill for its own ills.
Chinese Pharma Trending Up?
Outlining the four major areas driving China’s life sciences industry, which may be on the cusp of a new era in R&D and healthcare reform.
Plus ça change...
Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills.